StocksMedium•17 March 2026•
1 min read
Virbac Reports 7.9% Organic Revenue Growth in 2025 Despite Operational Hurdles
Key Facts
1Virbac achieved organic revenue growth of 7.9% at constant exchange rates and scope (CERS).
2The adjusted EBIT margin reached 16.3% despite production shutdowns and inventory write-offs.
3Volume/mix effect contributed ~5% to growth, while price increases added ~3%.
Animal health specialist Virbac released its annual financial results for 2025, demonstrating resilient performance amid operational challenges. The company achieved organic revenue growth of 7.9% at constant exchange rates and scope (CERS). The adjusted EBIT margin reached 16.3%, a solid figure considering temporary production shutdowns and inventory write-offs. Growth was primarily driven by a 5% contribution from volume and product mix, supplemented by a 3% increase from price adjustments. Strong momentum across key product categories and geographic regions helped offset the impact of one-off operational setbacks. These results highlight Virbac's robust underlying business performance and its ability to maintain healthy margins.